Presentación de PowerPoint
Clinical and Molecular Hepatology
Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study
Clinical and Molecular Hepatology
Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery | Scientific Reports
Detecting the silent epidemic of fatty liver disease
How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis? | SpringerLink
Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease
Non-invasive tests of non-alcoholic fatty liver disease | Chinese Medical Journal
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Pa
FibroScan - Because liver health matters
Transient elastography versus liver biopsy: discordance in evaluations for fibrosis and steatosis from a pathology standpoint | Modern Pathology
Individual patient data meta-analysis of controlled attenuation parameter ( CAP) technology for assessing steatosis - ScienceDirect
Frontiers | Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment
Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis - eClinicalMedicine
Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis - eClinicalMedicine
FibroScan - Because liver health matters
How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis? | SpringerLink
FibroScan - Because liver health matters
Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter - ScienceDirect
Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery | Scientific Reports
Diagnostics | Free Full-Text | Ultrasound-Based Diagnostic Methods: Possible Use in Fatty Liver Disease Area
The diagnostic conundrum in non-alcoholic fatty liver disease
PDF) FibroScan-AST Score Predicts 30-Day Mortality or Need for Mechanical Ventilation among Patients Hospitalized with COVID-19
